S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Google, Apple, Amazon give investors reason to fret
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Google, Apple, Amazon give investors reason to fret
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Google, Apple, Amazon give investors reason to fret
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Google, Apple, Amazon give investors reason to fret

Pfizer - PFE Stock Forecast, Price & News

-0.28 (-0.63%)
(As of 02/3/2023 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
23.74 million shs
Average Volume
26.25 million shs
Market Capitalization
$247.32 billion
P/E Ratio
Dividend Yield
Price Target

Pfizer MarketRank™ Forecast

Analyst Rating
2.33 Rating Score
18.3% Upside
$52.13 Price Target
Short Interest
0.66% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.08mentions of Pfizer in the last 14 days
Based on 65 Articles This Week
Insider Trading
Proj. Earnings Growth
From $3.35 to $3.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.47 out of 5 stars

Medical Sector

4th out of 1,028 stocks

Pharmaceutical Preparations Industry

3rd out of 501 stocks

PFE stock logo

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.


Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

Cathie Woods' Ark Innovation ETF Set To Rebound in 2023? (PFE)
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023?
Novavax Shares Jumped in January While Others Slipped (PFE)
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Pfizer stock is bouncing up and down after mixed Q4 earnings. There's been an emotional battle between bulls and bears but it's time for both to get rational
Drugmaker Pfizer starts low with 2023 earnings forecast
Pfizer surprised Wall Street on Tuesday by predicting bigger-than-expected sales drops this year for two key products: its COVID-19 vaccine and treatment
Pfizer tops 4Q expectations, starts low with 2023 forecast
COVID-19 vaccine booster shots and treatments for the virus helped push Pfizer to a better-than-expected final quarter of 2022
AbbVie Stock: Dividend King ABBV Overview (PFE)
MarketBeat Week in Review – 1/23- 1/27 (PFE)
Markets were pushing hard to continue the rally as.recession fears and layoff announcements offset two data points that suggest inflation may be easing
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
How Could GSK's RSV Vaccine Change its Valuation? (PFE)
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
Is the Pain Over for Baudax Bio Investors after a 70% Spike? (PFE)
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
When Does Pfizer Become A Bargain? (PFE)
With a price-to-earnings ratio of less than 9 and a dividend yield of 3.63% you have to be thinking that Pfizer may a bit of a bargain down here.
Better Buy: Novavax or BioNTech Stock?
Atlantic Securities Cuts Pfizer (NYSE:PFE) Price Target to $46.00
UBS Group Reiterates "$45.00" Price Target for Pfizer (NYSE:PFE)
Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.
Pfizer (NYSE:PFE) Price Target Cut to $53.00
StockNews.com Downgrades Pfizer (NYSE:PFE) to Buy
Pfizer (NYSE:PFE) Sees Strong Trading Volume After Strong Earnings
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 12/5 Dividend
Dividend Payable
Ex-Dividend for 3/3 Dividend
Last Earnings
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
$21.98 billion
Pretax Margin


Sales & Book Value

Annual Sales
$100.33 billion
Cash Flow
$7.32 per share
Book Value
$13.80 per share


Outstanding Shares
Free Float
Market Cap
$247.32 billion

Social Links

Key Executives

  • Albert Bourla
    Chairman, Chief Executive & Operating Officer
  • David M. Denton
    Chief Financial Officer & Executive Vice President
  • Mikael Dolsten
    Chief Scientific Officer & Research President
  • Maria Rivas
    Chief Medical Affairs Officer
  • Aida Habtezion
    Chief Medical Officer

PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings
or view top-rated stocks.

What is Pfizer's stock price forecast for 2023?

12 Wall Street analysts have issued 1 year price targets for Pfizer's stock. Their PFE share price forecasts range from $44.00 to $75.00. On average, they predict the company's stock price to reach $52.13 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price.
View analysts price targets for PFE
or view top-rated stocks among Wall Street analysts.

How have PFE shares performed in 2023?

Pfizer's stock was trading at $51.24 at the beginning of 2023. Since then, PFE stock has decreased by 14.0% and is now trading at $44.06.
View the best growth stocks for 2023 here

Are investors shorting Pfizer?

Pfizer saw a decline in short interest in the month of December. As of December 30th, there was short interest totaling 42,530,000 shares, a decline of 26.7% from the December 15th total of 58,020,000 shares. Based on an average daily volume of 21,080,000 shares, the days-to-cover ratio is currently 2.0 days.
View Pfizer's Short Interest

When is Pfizer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PFE earnings forecast

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, January, 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.11. The biopharmaceutical company had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a net margin of 31.27% and a trailing twelve-month return on equity of 43.02%. The business's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.08 EPS.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 9th. Shareholders of record on Friday, January 27th will be given a dividend of $0.41 per share on Friday, March 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.72%. The ex-dividend date of this dividend is Thursday, January 26th. This is an increase from the stock's previous quarterly dividend of $0.40.
Read our dividend analysis for PFE

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.64 per share and currently has a dividend yield of 3.70%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 29.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 41.31% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $3.25-$3.45 for the period, compared to the consensus EPS estimate of $4.38. The company issued revenue guidance of $67.0-$71.0 billion, compared to the consensus revenue estimate of $74.23 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.32%), Bank of Montreal Can (0.24%), New York State Common Retirement Fund (0.20%), DekaBank Deutsche Girozentrale (0.14%), New York State Teachers Retirement System (0.12%) and Zurcher Kantonalbank Zurich Cantonalbank (0.06%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock and William R Carapezzi Jr.
View institutional ownership trends

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $44.06.

How much money does Pfizer make?

Pfizer (NYSE:PFE) has a market capitalization of $247.32 billion and generates $100.33 billion in revenue each year. The biopharmaceutical company earns $21.98 billion in net income (profit) each year or $5.48 on an earnings per share basis.

How many employees does Pfizer have?

The company employs 79,000 workers across the globe.

Does Pfizer have any subsidiaries?
The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 2/4/2023 by MarketBeat.com Staff